Stock Scorecard



Stock Summary for Biocryst Pharmaceuticals Inc (BCRX) - $7.05 as of 11/20/2024 7:48:54 PM EST

Total Score

8 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BCRX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BCRX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BCRX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BCRX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BCRX (29 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 2
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for BCRX

BioCryst Launches ORLADEYO® ( berotralstat ) in Ireland - BioCryst Pharma ( NASDAQ:BCRX ) 11/18/2024 7:00:00 AM
BioCryst Launches ORLADEYO® ( berotralstat ) in Ireland 11/18/2024 7:00:00 AM
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema 11/7/2024 2:05:00 PM
BioCryst to Present at Upcoming Investor Conferences - BioCryst Pharma ( NASDAQ:BCRX ) 11/6/2024 12:00:00 PM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 11/5/2024 12:00:00 PM
BioCryst Pharmaceuticals ( BCRX ) Reports Q3 Loss, Tops Revenue Estimates 11/4/2024 1:10:00 PM
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® ( berotralstat ) - BioCryst Pharma ( NASDAQ:BCRX ) 10/24/2024 12:00:00 PM
How Much Upside is Left in BioCryst ( BCRX ) ? Wall Street Analysts Think 79.5% 10/23/2024 1:55:00 PM
BioCryst to Report Third Quarter 2024 Financial Results on November 4 - BioCryst Pharma ( NASDAQ:BCRX ) 10/21/2024 11:00:00 AM
BioCryst to Report Third Quarter 2024 Financial Results on November 4 10/21/2024 11:00:00 AM

Financial Details for BCRX

Company Overview

Ticker BCRX
Company Name Biocryst Pharmaceuticals Inc
Country USA
Description BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 7.05
Price 4 Years Ago 7.45
Last Day Price Updated 11/20/2024 7:48:54 PM EST
Last Day Volume 1,591,158
Average Daily Volume 2,197,697
52-Week High 8.88
52-Week Low 4.03
Last Price to 52 Week Low 74.94%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -12.07
Free Cash Flow Ratio 4.43
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.78
Total Cash Per Share 1.59
Book Value Per Share Most Recent Quarter -2.26
Price to Book Ratio 56.59
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 3.62
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 6

Share Statistics

Total Shares Outstanding 207,133,000
Market Capitalization 1,460,287,650
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 8.33%
Reported EPS 12 Trailing Months -0.61
Reported EPS Past Year -0.30
Reported EPS Prior Year -0.99
Net Income Twelve Trailing Months -123,817,000
Net Income Past Year -226,539,000
Net Income Prior Year -247,116,000
Quarterly Revenue Growth YOY 35.00%
5-Year Revenue Growth 76.06%
Operating Margin Twelve Trailing Months 0.07

Balance Sheet

Total Cash Most Recent Quarter 330,013,000
Total Cash Past Year 388,987,000
Total Cash Prior Year 424,310,000
Net Cash Position Most Recent Quarter -478,468,000
Net Cash Position Past Year -422,278,000
Long Term Debt Past Year 811,265,000
Long Term Debt Prior Year 733,279,000
Total Debt Most Recent Quarter 808,481,000
Equity to Debt Ratio Past Year -1.28
Equity to Debt Ratio Most Recent Quarter -1.38
Total Stockholder Equity Past Year -455,528,000
Total Stockholder Equity Prior Year -294,597,000
Total Stockholder Equity Most Recent Quarter -468,563,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -56,728,000
Free Cash Flow Per Share Twelve Trailing Months -0.27
Free Cash Flow Past Year -97,309,000
Free Cash Flow Prior Year -163,201,000

Options

Put/Call Ratio 0.05
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.05
MACD Signal 0.01
20-Day Bollinger Lower Band 6.78
20-Day Bollinger Middle Band 7.69
20-Day Bollinger Upper Band 8.59
Beta 1.89
RSI 39.35
50-Day SMA 6.43
150-Day SMA 9.04
200-Day SMA 10.18

System

Modified 11/20/2024 7:02:36 PM EST